HurlutinTM Lu-177 / Advanced Innovative Partners - LARVOL DELTA

Heroine01: A Phase I/II Multicenter, Open-Label Study of Lu-177-αvβ3-IAC, for the Treatment of Angiogenic Breast Cancer Patients. (clinicaltrials.gov) - P1/2 | N=100 | Not yet recruiting | Sponsor: Advanced Imaging Projects, LLC | Trial completion date: Aug 2024 ➔ Aug 2025 | Trial primary completion date: Aug 2024 ➔ Aug 2025

Trial completion date • Trial primary completion date • Breast Cancer • Oncology • Solid Tumor